The U.S. labels specify once-weekly dosing for Wegovy injections and Zepbound. The instructions for a missed weekly injection address an occasional missed dose and vary by product. Ask your prescriber before changing your injection schedule.[1][2]
What a reduced-frequency case series found
Researchers reviewed records for 30 adults whose weight had plateaued during weekly semaglutide or tirzepatide treatment. After switching to less frequent dosing, usually every other week, they were followed on that schedule for an average of 36.3 weeks. Mean weight was 74.1 kg at plateau and 72.4 kg during maintenance. The study included selected patients and had no comparison group that stayed on weekly treatment, so it cannot establish comparable effectiveness or safety.[3]
Studies of a lower weekly maintenance dose address a different change. They can inform a discussion with a prescriber about dose size, while the effects of taking injections less often remain uncertain.
What the bofanglutide trial tested
A 24-week, open-label phase 2b trial in Chinese adults with type 2 diabetes compared bofanglutide with weekly semaglutide 1 mg. HbA1c fell by 2.28 percentage points in the bofanglutide 18 mg every-two-weeks arm and by 1.60 with semaglutide. Gastrointestinal adverse events occurred in 81.8% to 87.3% across all bofanglutide arms, including the weekly arm, and in 51.9% of the semaglutide arm. Gan & Lee Pharmaceuticals funded the trial.[4]
If cost, availability, or side effects are making weekly treatment difficult, discuss those barriers with your prescriber and pharmacist. They can review options for the specific medication and formulation you use.